← Tra cứu cổ phiếu
Viewing Quý 1/2026Latest period →

iShareInvest Research

HOSE · Quý 1/2026

JVC

Đầu tư Y tế - Dược phẩm Việt Nam

Analysis of business results & financial statements · Quý 1/2026

▼▼ Declining sharply

Trailing net profit reached 36.9bn, fell 33.1bn compared with the same period last year. Key positives came from lower administrative expenses and lower tax. Offsetting pressure came mainly from lower gross profit, higher finance costs, lower financial income, and weaker other profit. Detailed impact is shown below:

See what is changing ↓
P/E
9.10x
P/B
0.52x
EPS
323
BVPS
5,666
ROE
6.2%
ROA
3.8%
Market price
2,940
19 Oct 2026

What Is Changing

On a TTM 2026Q1 basis, JVC is retaining some revenue, but margins are collapsing sharply — the growth momentum has held across consecutive periods. Costs or the profit mix are deteriorating faster than revenue is declining — this is the factor to watch ahead of everything else.

Profit bridge

Vs last year · TTM

  1. Administrative expenses
  2. Tax
  3. Gross profit
  4. Finance costs
  5. Financial income
  6. Other profit
Unit: VND bn. Green bars support profit; red bars reduce profit.

A single data point, or a trajectory?

Latest eight quarters · Quý 1/2026

MetricQ1'26Q4'25Q3'25Q2'25Q1'25Q4'24Q3'24Q2'24
Revenue159.1284.9161.2136.3181.2188.7148.0157.6
LNST10.89.912.63.124.528.08.49.3
Net margin6.79%3.46%7.83%2.27%13.50%14.82%5.71%5.89%

Revenue

159bn

Net income

11bn

Net margin

6.79%

A closer look at what is happening inside the business

A company's statements are read with the questions that fit its type of business.

01

Is the profit sustainable?

Margins narrowed but earnings quality remains clean — pressure is mainly operational.

What is driving the margin?

▼▼

Net margin fell to 4.90%, losing 5.5pp. The main pressure is Gross margin fell 6.0pp, outweighing the improvement in SG&A / Revenue fell 3.2pp (with lingering pressure from Net financial result / Revenue fell 3.0pp and Other profit / Revenue fell 0.7pp).

The pressure comes from non-core items while core operations hold their rhythm — margin has a basis to recover once this factor passes.

Net Margin
4.90%
−5.5pp
Gross Margin
19.50%
−6.0pp
SG&A / Revenue
12.68%
−3.2pp

TTM YoY · 2025Q1 -> 2026Q1

02

Is capital being used efficiently?

Capital efficiency is declining — check whether the drag is from margins or turnover.

Is capital being deployed efficiently?

▼▼

ROIC fell to 3.57%, losing 5.6pp. That translates to 3.57 in after-tax operating profit for every 100 units of operating capital. Both NOPAT margin narrowed 4.8pp and capital turnover fell 0.17x, while invested capital expanded strongly by 205bn — pressure came from both operational efficiency and asset efficiency.

Pressure came from the margin side — core operations are weakening, not just a temporary asset-management issue.

ROIC remains low

ROIC is currently 3.57% — below the typical cost-of-capital threshold; worth tracking whether upcoming periods can rise above this level.

Balance Sheet

▲

ROIC declined — the balance sheet shows how capital is being deployed. Capital structure is balanced — liabilities at 0.71x equity, net debt at 0.57x equity.

Inventory ended the period at 121.4bn, roughly 11.3% of total assets.

Over the last 12 months, working capital released 100.6bn of cash, mainly thanks to lower receivables and lower inventories.

Working Capital Efficiency

▲▲

Working capital is being managed more efficiently, supporting overall capital efficiency. Cash conversion cycle improved by 49.2 days versus the same period last year. The main moves came from DIO rose 1.6 days, DSO fell 55.6 days, and DPO fell 4.7 days.

Improvement comes mainly from faster receivables collection — reflects the quality of receivables management.

Cash conversion cycle remains stretched

CCC stands at 180.7 days, suggesting that working capital remains tied up for a relatively long operating cycle.

Inventory turnover is slowing

DIO increased by +1.6 days, suggesting more capital is being tied up in inventories.

DuPont

What drives ROE?

Net margin 4.9% -5.5pp
Asset turnover 0.76x -0.13x
Financial leverage 1.63x +0.21x
ROE 6.1% -7.0pp

ROE fell from 13.1% to 6.1% — net margin weakened the most, though leverage still provided support.

03

Is financial risk significant?

Check leverage, liquidity, and cash-flow conversion.

Leverage & Liquidity

▼▼

Leverage warrants monitoring, with net debt / equity at 0.57x and interest coverage only at 1.91x.

At present, short-term debt accounts for 93.1% of total debt, cash equals 7.6% of debt, and total debt stands at 390.3bn.

Interest coverage is thin

Interest coverage is 1.91x, leaving limited room to absorb financing costs.

Short-term refinancing pressure is meaningful

Short-term debt accounts for 93.1% of total debt, raising near-term refinancing needs.

Net Debt / Equity
0.57x
+0.27x
Interest Coverage
1.91x
−7.85x
Cash / Debt
7.6%
+1.2pp
Short-term Debt / Total Debt
93.1%
−1.9pp

TTM YoY · 2025Q1 -> 2026Q1

Cash Flow

●

Operating cash flow reached -88.5bn in 2025, against investing cash flow of -101.1bn.

Post-investment cash flow was negative +189.6bn. Financing cash flow was positive +199.3bn.

CFO / net income was 3,58 lần.

Track how much investment can be funded internally from operating cash flow.

Cash capex or FCF data is incomplete, so the cash-conversion view is only partial.

Research synthesis

What this reporting period is showing

The business is under real pressure, but the current picture has not turned broadly adverse. A notable area has clearly weakened, making the near-term outlook hard to call bright; even so, other parts of the business are still holding up, with margins remain under pressure remaining the main constraint, with net margin down 5.5 pp. The next watchpoint is the earnings mix, when non-core contribution is 15.1%.

  • Watchpoint: cash flow is currently keeping pace with accounting earnings, with CFO / net income at 3.58x. Even so, net financial result still accounts for 15.1% of PBT, so the earnings mix still needs monitoring.
  • Key risk: profitability remains under pressure, with trailing-12M net margin at 4.90% after a 5.5pp decline versus the same period last year.

Questions for the next period

  1. Durability of revenue growth after the current +9,8% YoY pace.

  2. Ability to hold margins around the current 4.90% level.

  3. Cash-flow quality, with operating cash flow currently at -88.5bn in 2025.

From one stock to the whole portfolio

Where does this stock stand
among the rest of your investments?

Each stock is only one part of the wider picture. Looking at investments side by side makes their contribution, risks and opportunities across the portfolio clearer.

How much does this stock
contribute to the portfolio?

Its weight and influence across the assets held for investment.

Is the portfolio
well balanced?

How holdings, sectors and asset groups are distributed in relation to overall risk.

What other opportunities
or risks may be present?

What becomes visible only when investments are viewed together rather than one ticker at a time.

View my portfolio